Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 10/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | DAGLA | Q9Y4D2 | 6/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5489548 | 1.00 | FAAH (0.44) | FAAHNPC1RAB9ADAGLASMN1; SMN2 | |
| SCHEMBL5490451 | 0.75 | RAB9A (0.44) | NPC1RAB9ASMN1; SMN2TP53MAPT | |
| SCHEMBL5490453 | 0.75 | RAB9A (0.44) | NPC1RAB9ASMN1; SMN2TP53MAPT | |
| SCHEMBL3620326 | 0.74 | NPC1 (0.40) | FAAHNPC1RAB9ADAGLATP53 | |
| SCHEMBL3622707 | 0.73 | FAAH (0.43) | FAAHDAGLATP53POLBMAPT | |
| SCHEMBL5522225 | 0.73 | FAAH (0.43) | FAAHDAGLATP53POLBMAPT | |
| SCHEMBL3620329 | 0.73 | FAAH (0.39) | FAAHNPC1RAB9ADAGLATP53 | |
| SCHEMBL12259654 | 0.73 | AKT1 (0.42) | FAAHNPC1RAB9ADAGLATP53 | |
| SCHEMBL5693650 | 0.72 | HDAC4 (0.43) | — | |
| SCHEMBL38654805 | 0.71 | FAAH (0.47) | FAAHNPC1RAB9ADAGLASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070276019-A1 | Haloalkyl Containing Compounds as Cysteine Protease Inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276019-A1 | Haloalkyl Containing Compounds as Cysteine Protease Inhibitors | CTSF, CTSS, CTSE | FAAH 213/4885NPC1 123/4885RAB9A 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.